This information was published on 2025-08-19T18:23:48 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2573783 |
| (220) |
05 Aug 2025
|
| (300) |
US, 05 Feb 2025, 99030058
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment and prevention of oncological, hematological, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; stem cells for medical purposes; diagnostic radiopharmaceutical preparations; diagnostic preparations for medical purposes; radiopharmaceutical preparations for the treatment of cancer and immune system related diseases and disorders. |
| (540) | FYMILSI |
| (550) | Word |
| (730) |
Bristol-Myers Squibb Company
|
| (750) |
Spruson & Ferguson
|
Find out more about publications on the About page.